Published in Am J Hum Genet on December 01, 1997
Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency. Am J Hum Genet (1999) 1.99
A European multicenter study of phenylalanine hydroxylase deficiency: classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotype. Am J Hum Genet (1998) 1.78
Phenylketonuria: an inborn error of phenylalanine metabolism. Clin Biochem Rev (2008) 1.74
Phenylketonuria in adulthood: a collaborative study. J Inherit Metab Dis (2002) 1.61
Phenylalanine tolerance can already reliably be assessed at the age of 2 years in patients with PKU. J Inherit Metab Dis (2009) 1.52
Prevalence of tetrahydrobiopterine (BH4)-responsive alleles among Austrian patients with PAH deficiency: comprehensive results from molecular analysis in 147 patients. J Inherit Metab Dis (2012) 1.44
Tetrahydrobiopterin monotherapy for phenylketonuria patients with common mild mutations. Eur J Pediatr (2002) 1.39
Predicted effects of missense mutations on native-state stability account for phenotypic outcome in phenylketonuria, a paradigm of misfolding diseases. Am J Hum Genet (2007) 1.24
Defective folding and rapid degradation of mutant proteins is a common disease mechanism in genetic disorders. J Inherit Metab Dis (2000) 1.00
Missense mutations in the N-terminal domain of human phenylalanine hydroxylase interfere with binding of regulatory phenylalanine. Am J Hum Genet (2001) 0.95
The role of chaperone-assisted folding and quality control in inborn errors of metabolism: protein folding disorders. J Inherit Metab Dis (2001) 0.91
What we know that could influence future treatment of phenylketonuria. J Inherit Metab Dis (2008) 0.90
Biochemical characterization of mutant phenylalanine hydroxylase enzymes and correlation with clinical presentation in hyperphenylalaninaemic patients. J Inherit Metab Dis (2008) 0.88
Linking genotypes database with locus-specific database and genotype-phenotype correlation in phenylketonuria. Eur J Hum Genet (2014) 0.86
Reassessment of phenylalanine tolerance in adults with phenylketonuria is needed as body mass changes. Mol Genet Metab (2009) 0.86
Protein stability and in vivo concentration of missense mutations in phenylalanine hydroxylase. Proteins (2011) 0.84
Missense mutations in the phenylalanine hydroxylase gene (PAH) can cause accelerated proteolytic turnover of PAH enzyme: a mechanism underlying phenylketonuria. J Inherit Metab Dis (1999) 0.83
Tetrahydrobiopterin responsiveness in phenylketonuria. Two new cases and a review of molecular genetic findings. J Inherit Metab Dis (2002) 0.82
Brain phenylalanine concentration in the management of adults with phenylketonuria. J Inherit Metab Dis (2000) 0.81
A structural hypothesis for BH4 responsiveness in patients with mild forms of hyperphenylalaninaemia and phenylketonuria. J Inherit Metab Dis (2001) 0.80
"MY PKU": increasing self-management in patients with phenylketonuria. A randomized controlled trial. Orphanet J Rare Dis (2011) 0.80
Molecular Genetics and Genotype-Based Estimation of BH4-Responsiveness in Serbian PKU Patients: Spotlight on Phenotypic Implications of p.L48S. JIMD Rep (2012) 0.79
The Molecular Bases of Phenylketonuria (PKU) in New South Wales, Australia: Mutation Profile and Correlation with Tetrahydrobiopterin (BH4) Responsiveness. JIMD Rep (2013) 0.79
Missense variants in CFTR nucleotide-binding domains predict quantitative phenotypes associated with cystic fibrosis disease severity. Hum Mol Genet (2014) 0.78
Identification of mutations underlying 20 inborn errors of metabolism in the United Arab Emirates population. Genet Test Mol Biomarkers (2011) 0.78
Outcomes of phenylketonuria with relevance to follow-up. JIMD Rep (2011) 0.77
Chaperone-like therapy with tetrahydrobiopterin in clinical trials for phenylketonuria: is genotype a predictor of response? JIMD Rep (2011) 0.76
An ongoing debate over phenylalanine hydroxylase deficiency in phenylketonuria. J Clin Invest (1998) 0.75
Mutations of the phenylalanine hydroxylase gene in Iranian patients with phenylketonuria. Springerplus (2015) 0.75
Role of catalase and superoxide dismutase activities on oxidative stress in the brain of a phenylketonuria animal model and the effect of lipoic acid. Cell Mol Neurobiol (2012) 0.75
Phenylketonuria: translating research into novel therapies. Transl Pediatr (2014) 0.75
Micronutrients, Essential Fatty Acids and Bone Health in Phenylketonuria. Ann Nutr Metab (2017) 0.75
Discordant PKU phenotype in one family due to disparate genotypes and a novel mutation. J Inherit Metab Dis (2004) 0.75
The molecular basis of dominance. Genetics (1982) 11.35
Nucleotide sequence of a full-length complementary DNA clone and amino acid sequence of human phenylalanine hydroxylase. Biochemistry (1985) 4.78
Extensive restriction site polymorphism at the human phenylalanine hydroxylase locus and application in prenatal diagnosis of phenylketonuria. Am J Hum Genet (1985) 3.77
Cloned human phenylalanine hydroxylase gene allows prenatal diagnosis and carrier detection of classical phenylketonuria. Nature (1984) 2.82
Treatment of phenylketonuria with a diet low in phenylalanine. Br Med J (1955) 2.51
Molecular structure and polymorphic map of the human phenylalanine hydroxylase gene. Biochemistry (1986) 2.49
Molecular basis of phenotypic heterogeneity in phenylketonuria. N Engl J Med (1991) 2.40
Studies on phenylketonuria. I. Restricted phenylalanine intake in phenylketonuria. J Clin Invest (1955) 2.03
The influence of phenylalanine intake on the chemistry and behaviour of a phenyl-ketonuric child. Acta Paediatr (1954) 1.94
In vivo assessment of mutations in the phenylalanine hydroxylase gene by phenylalanine loading: characterization of seven common mutations. Eur J Pediatr (1995) 1.69
Quantification of the importance of individual steps in the control of aromatic amino acid metabolism. Biochem J (1986) 1.68
Molecular genetics of phenylketonuria in Mediterranean countries: a mutation associated with partial phenylalanine hydroxylase deficiency. Am J Hum Genet (1989) 1.58
Missense mutations associated with RFLP haplotypes 1 and 4 of the human phenylalanine hydroxylase gene. Am J Hum Genet (1990) 1.45
Correlation between polymorphic DNA haplotypes at phenylalanine hydroxylase locus and clinical phenotypes of phenylketonuria. J Pediatr (1987) 1.22
Molecular analysis of the inheritance of phenylketonuria and mild hyperphenylalaninemia in families with both disorders. N Engl J Med (1986) 1.17
Mutation nomenclature: nicknames, systematic names, and unique identifiers. Hum Mutat (1996) 1.14
Normal plasma free amino acid values in adults: the influence of some common physiological variables. Metabolism (1985) 1.12
Characterization of phenylketonuria alleles in the Italian population. Eur J Hum Genet (1995) 1.12
In vitro expression analysis of mutations in phenylalanine hydroxylase: linking genotype to phenotype and structure to function. Hum Mutat (1998) 1.05
Delineation of the catalytic core of phenylalanine hydroxylase and identification of glutamate 286 as a critical residue for pterin function. J Biol Chem (1994) 1.05
Structural characterization of the 5' regions of the human phenylalanine hydroxylase gene. Biochemistry (1992) 1.04
In vivo disposal of phenylalanine in phenylketonuria: a study of two siblings. J Inherit Metab Dis (1996) 1.00
The PAH mutation analysis consortium database: update 1996. Nucleic Acids Res (1997) 0.97
PKU mutation G46S is associated with increased aggregation and degradation of the phenylalanine hydroxylase enzyme. Hum Mutat (1996) 0.97
Phenylketonuria missense mutations in the Mediterranean. Genomics (1991) 0.97
Discordant phenylketonuria phenotypes in one family: the relationship between genotype and clinical outcome is a function of multiple effects. J Med Genet (1995) 0.96
Further studies of the role of Ser-16 in the regulation of the activity of phenylalanine hydroxylase. Proc Natl Acad Sci U S A (1995) 0.96
Molecular heterogeneity of nonphenylketonuria hyperphenylalaninemia in 25 Danish patients. Genomics (1994) 0.96
In vitro and in vivo correlations for I65T and M1V mutations at the phenylalanine hydroxylase locus. Hum Mutat (1992) 0.96
Two missense mutations causing mild hyperphenylalaninemia associated with DNA haplotype 12. Hum Mutat (1992) 0.96
PAH deficiency in Italy: correlation of genotype with phenotype in the Sicilian population. J Inherit Metab Dis (1996) 0.96
Analysis of phenylalanine hydroxylase genotypes and hyperphenylalaninemia phenotypes using L-[1-13C]phenylalanine oxidation rates in vivo: a pilot study. Pediatr Res (1997) 0.95
Comparison of genotype and intellectual phenotype in untreated PKU patients. J Med Genet (1993) 0.94
Expression of rat liver phenylalanine hydroxylase in insect cells and site-directed mutagenesis of putative non-heme iron-binding sites. J Biol Chem (1993) 0.94
Relation between genotype and phenotype in Swedish phenylketonuria and hyperphenylalaninemia patients. Eur J Pediatr (1993) 0.93
Phenylalanine hydroxylase genotypes, predicted residual enzyme activity and phenotypic parameters of diagnosis and treatment of phenylketonuria. Eur J Pediatr (1996) 0.90
Different clinical manifestations of hyperphenylalaninemia in three siblings with identical phenylalanine hydroxylase genes. Am J Hum Genet (1991) 0.88
Mutation analysis in families with discordant phenotypes of phenylalanine hydroxylase deficiency. Inheritance and expression of the hyperphenylalaninaemias. J Inherit Metab Dis (1994) 0.88
Evidence in Latin America of recurrence of V388M, a phenylketonuria mutation with high in vitro residual activity. Am J Hum Genet (1995) 0.88
Is there a paradigm shift in genetics? Lessons from the study of human diseases. Mol Phylogenet Evol (1996) 0.85
Phenylketonuria in Poland: 66% of PKU alleles are caused by three mutations. Hum Genet (1991) 0.82
Genotype-phenotype correlations in phenylketonuria. Clin Chim Acta (1993) 0.82
Non-phenylketonuria hyperphenylalaninaemia in Northern Ireland: frequent mutation allows screening and early diagnosis. Hum Mutat (1994) 0.81
Phenylketonuria genotypes correlated to metabolic phenotype groups in Norway. Eur J Pediatr (1996) 0.81
Three prevalent mutations in a patient with phenylalanine hydroxylase deficiency: implications for diagnosis and genetic counselling. J Med Genet (1996) 0.81
Five novel missense mutations of the phenylalanine hydroxylase gene in phenylketonuria. Hum Mutat (1994) 0.80
Phenylketonuria in southern Poland: a new splice mutation in intron 9 at the PAH locus. Hum Mutat (1994) 0.80
Phenylketonuria--genotypes and phenotypes. N Engl J Med (1991) 0.78
Recurrent nonsense mutation in exon 7 of the phenylalanine hydroxylase gene. Hum Genet (1991) 0.78
A missense mutation, S349P, completely inactivates phenylalanine hydroxylase in north African Jews with phenylketonuria. Hum Genet (1993) 0.77
Expression analysis of mutation P244L, which causes mild hyperphenylalaninemia. Hum Mutat (1995) 0.77
Phenotype distribution in the Spanish phenylketonuria population and related genotypes. J Inherit Metab Dis (1994) 0.77
Novel missense mutation in the phenylalanine hydroxylase gene leading to complete loss of enzymatic activity. Hum Mutat (1995) 0.77
Different phenotypic manifestations associated with identical phenylketonuria genotypes in two Spanish families. J Inherit Metab Dis (1994) 0.77
Identification of Gln313 and Pro327 as residues critical for substrate inhibition in tyrosine hydroxylase. J Neurochem (1996) 0.77
Heterogeneity of mutations in Bulgarian phenylketonuria haplotype 1 and 4 alleles. Clin Genet (1992) 0.77
Phenylketonuria: variable phenotypic outcomes of the R261Q mutation and maternal PKU in the offspring of a healthy homozygote. J Med Genet (1993) 0.76
A rapid procedure for extracting genomic DNA from leukocytes. Nucleic Acids Res (1991) 3.89
Advocacy and compliance in genetic screening. Behavior of physicians and clients in a voluntary program of testing for the Tay-Sachs gene. N Engl J Med (1974) 3.47
Hypophosphatemia: mouse model for human familial hypophosphatemic (vitamin D-resistant) rickets. Proc Natl Acad Sci U S A (1976) 2.59
The use of biochemical data in screening for mutant alleles and in genetic counselling. Ann Hum Genet (1974) 2.43
Knowledge about and attitudes toward genetic screening among high-school students: the Tay-Sachs experience. Pediatrics (1977) 2.29
Beta-thalassemia disease prevention: genetic medicine applied. Am J Hum Genet (1984) 2.27
The frequency of genetic disease and congenital malformation among patients in a pediatric hospital. Can Med Assoc J (1973) 2.22
The effect of Mendelian disease on human health: a measurement. Am J Med Genet (1985) 2.18
Transient tyrosinemia of the newborn: dietary and clinical aspects. Pediatrics (1967) 2.15
Screening, counselling and treatment of hereditary metabolic disease; a survey of resources in Canada. Can Med Assoc J (1974) 2.11
A private view of heterozygosity: eight-year follow-up study on carriers of the Tay-Sachs gene detected by high school screening in Montreal. Am J Med Genet (1984) 2.04
Cost-benefit analysis of a thalassemia disease prevention program. Am J Public Health (1985) 1.99
The HUGO Mutation Database Initiative. Science (1998) 1.95
Twenty-year outcome analysis of genetic screening programs for Tay-Sachs and beta-thalassemia disease carriers in high schools. Am J Hum Genet (1996) 1.94
Carrier screening for Tay-Sachs disease. Lancet (1990) 1.92
On the application of knowledge to the patient with genetic disease. Prog Med Genet (1973) 1.84
Science's neglected legacy. Nature (2000) 1.77
Proof of "disease causing" mutation. Hum Mutat (1998) 1.68
What young people think and do when the option for cystic fibrosis carrier testing is available. J Med Genet (1993) 1.68
Monogenic traits are not simple: lessons from phenylketonuria. Trends Genet (1999) 1.67
Genetics and Medicine: an evolving relationship. Science (1978) 1.65
Recommendations for locus-specific databases and their curation. Hum Mutat (2008) 1.49
Loss of a parathyroid hormone-sensitive component of phosphate transport in X-linked hypophosphatemia. Science (1972) 1.48
Use of phosphate and vitamin D to prevent dwarfism and rickets in X-linked hypophosphatemia. N Engl J Med (1972) 1.46
Renal handling of phosphate in vivo and in vitro by the X-linked hypophosphatemic male mouse: evidence for a defect in the brush border membrane. Kidney Int (1978) 1.45
The defect in transcellular transport of phosphate in the nephron is located in brush-border membranes in X-linked hypophosphatemia (Hyp mouse model). Can J Biochem (1978) 1.45
Neonatal hypertyrosinemia and evidence for deficiency of ascorbic acid in Arctic and subarctic peoples. Can Med Assoc J (1975) 1.42
Novel PKU mutation on haplotype 2 in French-Canadians. Am J Hum Genet (1989) 1.40
Serum 1,25-dihydroxyvitamin D levels in normal subjects and in patients with hereditary rickets or bone disease. N Engl J Med (1978) 1.40
[Tay-Sachs disease: prenatal detection and diagnosis]. Union Med Can (1972) 1.36
Labile methyl group balances in the human: the role of sarcosine. Metabolism (1980) 1.34
Endogenous renal clearance rates of free amino acids in pre-pubertal children. (Employing an accelerated procedure for elution chromatography of basic amino acids on ion exchange resin). Pediatrics (1965) 1.34
Phenylketonuria: epitome of human biochemical genetics (first of two parts). N Engl J Med (1980) 1.30
Genetic variants of Tay-Sachs disease: Tay-Sachs disease and Sandhoff's disease in French Canadians, juvenile Tay-Sachs disease in Lebanese Canadians, and a Tay-Sachs screening program in the French-Canadian population. Prog Clin Biol Res (1977) 1.30
Use of dithiothreitol to correct cystine storage in cultured cystinotic fibroblasts. Lancet (1970) 1.30
Thiamine-responsive maple-syrup-urine disease. Lancet (1971) 1.29
Familial cold urticaria. Clin Exp Dermatol (1993) 1.29
Hyperparathyroidism as the cause of hyperaminoaciduria and phosphaturia in human vitamin D deficiency. Pediatr Res (1967) 1.29
Recurrent mutation, gene conversion, or recombination at the human phenylalanine hydroxylase locus: evidence in French-Canadians and a catalog of mutations. Am J Hum Genet (1990) 1.28
Phenylketonuria and other phenylalanine hydroxylation mutants in man. Annu Rev Genet (1980) 1.27
Management of hereditary metabolic disease. The role of allied health personnel. N Engl J Med (1971) 1.26
A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase. Proc Natl Acad Sci U S A (1999) 1.25
Outcome of early and long-term management of classical maple syrup urine disease. Pediatrics (1981) 1.22
PAH Mutation Analysis Consortium Database: a database for disease-producing and other allelic variation at the human PAH locus. Nucleic Acids Res (1996) 1.21
The characterization of hereditary abnormalities of keratin: Clouston's ectodermal dysplasia. Birth Defects Orig Artic Ser (1971) 1.20
Diagnosis and treatment: interpreting the positive screening test in the newborn infant. Pediatrics (1967) 1.20
Prevention of mental retardation in offspring of hyperphenylalaninemic mothers. Am J Public Health (1982) 1.19
Heterogeneity in genetic control of phenylalanine metabolism in man. Nature (1968) 1.19
Branched-chain alpha-keto acids isolated as oxime derivatives: relationship to the corresponding hydroxy acids and amino acids in maple syrup urine disease. Metabolism (1974) 1.18
Cystic fibrosis genotypes and views on screening are both heterogeneous and population related. Am J Hum Genet (1992) 1.17
The application of an automated hexosaminidase assay to genetic screening. Clin Chim Acta (1974) 1.15
X-linked hypophosphatemia: effect of calcitriol on renal handling of phosphate, serum phosphate, and bone mineralization. J Clin Endocrinol Metab (1981) 1.15
The Gy mutation: another cause of X-linked hypophosphatemia in mouse. Proc Natl Acad Sci U S A (1986) 1.14
Results of mass screening for hyperaminoacidemias in the newborn infant. Am J Dis Child (1969) 1.14
Mutation nomenclature: nicknames, systematic names, and unique identifiers. Hum Mutat (1996) 1.14
Normal plasma free amino acid values in adults: the influence of some common physiological variables. Metabolism (1985) 1.12
Phenylketonuria: epitome of human biochemical genetics (second of two parts). N Engl J Med (1980) 1.11
PAHdb: a locus-specific knowledgebase. Hum Mutat (2000) 1.11
Amino acid transport in mammalian kidney: Multiple systems for imino acids and glycine in rat kidney. Am J Physiol (1970) 1.11
Age at onset and causes of disease. Perspect Biol Med (1986) 1.09
Hereditary tyrosinemia and tyrosyluria: clinical report of four patients. Can Med Assoc J (1967) 1.08
Demonstration of a new mammalian isoleucine catabolic pathway yielding an Rseries of metabolites. Biochem J (1976) 1.08
Germline mutations in the von Hippel-Lindau (VHL) gene in patients from Poland: disease presentation in patients with deletions of the entire VHL gene. J Med Genet (2002) 1.07
Specificity of transport of neutral and basic amino acids in rat kidney. Am J Physiol (1967) 1.07
Cerebral dysgenesis and lactic acidemia: an MRI/MRS phenotype associated with pyruvate dehydrogenase deficiency. Pediatr Neurol (1994) 1.07
Evidence for origin, by recurrent mutation, of the phenylalanine hydroxylase R408W mutation on two haplotypes in European and Quebec populations. Hum Mol Genet (1994) 1.06
Hereditary tyrosinemia and tyrosyluria in a French Canadian geographic isolate. Am J Dis Child (1967) 1.06
On the heritability of rickets, a common disease (Mendel, mammals and phosphate). Johns Hopkins Med J (1981) 1.06
Cystinuria: increased prevalence in patients with mental disease. N Engl J Med (1970) 1.06
Hyperdibasicaminoaciduria: an inherited disorder of amino acid transport. Pediatr Res (1968) 1.05
Renal tubular transport of proline, hydroxyproline, and glycine. 3. Genetic basis for more than one mode of transport in human kidney. J Clin Invest (1968) 1.05
Cystic fibrosis carrier screening by DNA analysis: a pilot study of attitudes among participants. Am J Hum Genet (1991) 1.05
Amino acid metabolism and its disorders. Major Probl Clin Pediatr (1973) 1.05
A "new" disorder of isoleucine catabolism. Lancet (1971) 1.05
Improved detection of beta-thalassaemia carriers by a two-test method. Hum Genet (1977) 1.05
In vitro expression analysis of mutations in phenylalanine hydroxylase: linking genotype to phenotype and structure to function. Hum Mutat (1998) 1.05
Maple syrup urine disease: interrelations between branched-chain amino-, oxo- and hydroxyacids; implications for treatment; associations with CNS dysmyelination. J Inherit Metab Dis (1992) 1.04
GM1-gangliosidosis without chondrodystrophy or visceromegaly. B-galactosidase deficiency with gangliosidosis and the excessive excretion of a keratan sulfate. Neurology (1970) 1.03
'Celtic' phenylketonuria chromosomes found? Evidence in two regions of Quebec Province. Eur J Hum Genet (1993) 1.03
Renal adaptation to phosphate deprivation in the Hyp mouse with X-linked hypophosphatemia. Can J Biochem (1979) 1.02
Sialic acid and cardiovascular mortality. BMJ (1991) 1.01
Quantitation of beta-thalassemia genes in Quebec immigrants of Mediterranean, southeast Asian, and Asian Indian origins. Clin Invest Med (1991) 1.01
Adolescent cystinosis: comparisons with infantile and adult forms. Pediatrics (1971) 1.01
The adolescent copes with genetic screening: a study of Tay-Sachs screening among high-school students. Prog Clin Biol Res (1977) 1.00
Plasma amino acids: screening, quantitation, and interpretation. Am J Clin Nutr (1971) 1.00
The ontogeny of amino acid transport in rat kidney. I. Effect on distribution ratios and intracellular metabolism of proline and glycine. Biochim Biophys Acta (1971) 1.00
The Hartnup phenotype: Mendelian transport disorder, multifactorial disease. Am J Hum Genet (1987) 1.00
Amino acid transport in kidney. Heterogeneity of alpha-aminoisobutyric uptake. J Biol Chem (1968) 0.99
The clinical phenotype and outcome of mitochondrial acetoacetyl-CoA thiolase deficiency (beta-ketothiolase or T2 deficiency) in 26 enzymatically proved and mutation-defined patients. Mol Genet Metab (2001) 0.99
X-linked hypophosphataemic rickets: Inadequate therapeutic response to 1,25-dihydroxycholecalciferol. Lancet (1973) 0.98
Observations on the composition of milk-substitute products for treatment of inborn errors of amino acid metabolism. Comparisons with human milk. A proposal to rationalize nutrient content of treatment products. Am J Clin Nutr (1979) 0.98
An inherited disorder of isoleucine catabolism causing accumulation of alpha-methylacetoacetate and alpha-methyl-beta -hydroxybutyrate, and intermittent metabolic acidosis. Pediatr Res (1973) 0.97
The PAH mutation analysis consortium database: update 1996. Nucleic Acids Res (1997) 0.97
Metabolism of methylmalonic acid in rats. Is methylmalonyl-coenzyme a racemase deficiency symptomatic in man? J Clin Invest (1983) 0.97
The birth prevalence of PKU in populations of European, South Asian and sub-Saharan African ancestry living in South East England. Ann Hum Genet (2008) 0.97
Is hereditary histidinaemia harmful? Lancet (1974) 0.97